Sertaconazole: updated review of a topical antifungal agent.
Sertaconazole: updated review of a topical antifungal agent.
复制标题
DOI：
10.1586/14787210.3.3.333
复制
发表时间：
2005-06-01
影响因子：
5.7
通讯作者：
Quindos, Guillermo
中科院分区：
文献类型：
--
作者：
Carrillo-Munoz, Alfonso J;Giusiano, Gustavo;Quindos, Guillermo
舍他康唑是一种咪唑类抗真菌药物，在体外对致病真菌具有相当的活性。在动物模型、临床和毒理学试验中进行的各种研究证实了舍他康唑在皮肤科和妇科浅表真菌病的局部治疗中的价值。在皮肤真菌病和花斑癣的局部治疗方面取得了多年的临床经验后，该物质已在欧洲被批准用于妇科念珠菌病。舍他康唑具有广泛的作用谱，包括酵母菌和皮肤真菌，它也对细菌，主要是革兰氏阳性球菌有活性，使其在治疗多种微生物感染方面非常有效。美国食品药品监督管理局最近批准了该分子，以及每周给药一次用于治疗甲真菌病的舍他康唑新制剂的出现，都是与该产品上市过程相关的数据。
Sertaconazole is an imidazole-type antifungal agent that has shown considerable in vitro activity against pathogenic fungi. Various studies carried out in animal models, clinical and toxicologic trials have confirmed the value of sertaconazole in the topical treatment of superficial mycoses in dermatology and gynecology. After several years of clinical experience in the topical treatment of dermatophytosis and Tinea versicolor, the substance has been approved for gynecologic candidiasis in Europe. Sertaconazole has a wide action spectrum that includes yeasts and dermatophyte fungi, and it is also active against bacteria, mainly Gram-positive cocci, making it highly efficient in the treatment of polymicrobial infections. The recent approval of the molecule by the US Food and Drug Administration, and the appearance of a new formulation of sertaconazole for the treatment of onychomycoses on a weekly administrative basis, are all data relevant to the process of marketing the product.